Beacon Biosignals closed an $86 million financing to build a large brain‑wave repository aimed at accelerating discovery of neurological disease diagnostics and therapeutics. The company plans to scale data collection across clinical and research sites to power biomarker development and proprietary models. The raise signals investor appetite for data‑centric neurology startups that combine long‑duration electrophysiology with analytics. Beacon’s strategy—amassing labeled, longitudinal EEG datasets—targets gaps in drug development and digital diagnostics for conditions such as epilepsy, neurodegeneration, and mood disorders.